SCHEMBL27415470

SCHEMBL27415470

Cn1nc(OCC(F)(F)F)cc1NC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.44
PKM P14618 1/20 0.44
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 1/20 0.38
GSK3B P49841 1/20 0.37
DYRK1A Q13627 1/20 0.37
CYP17A1 P05093 1/20 0.36
BRD9 Q9H8M2 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PTGER1 P34995 1/20 0.35
AR P10275 1/20 0.35
RORC P51449 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
MAP4K4 O95819 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21604145 0.90 MAPK14 (0.46) MAPK14PKMSMN1; SMN2MEN1KMT2A
SCHEMBL21597716 0.85 MAPK14 (0.46) MAPK14PKMGSK3BDYRK1ACYP17A1
SCHEMBL28620607 0.83 MAPK14 (0.44) MAPK14PKMNPC1RAB9AMAPT
SCHEMBL21597704 0.81 MAPK14 (0.46) MAPK14NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL28617347 0.81 MAPK14 (0.42) MAPK14PKMNPC1RAB9AMAPT
SCHEMBL21597824 0.80 MAPK14 (0.43) MAPK14PKMGSK3BDYRK1A
SCHEMBL17517053 0.79 PKM (0.49) MAPK14PKMSMN1; SMN2MEN1KMT2A
SCHEMBL28626969 0.79 MAPK14 (0.43) MAPK14NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL21604120 0.75 CACNB4 (0.43) MAPK14GSK3BDYRK1ACYP17A1BRD9
SCHEMBL35210874 0.75 SMN1; SMN2 (0.57) MAPK14PKMSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 MAPK14 1656/4885PKM 4689/4885NPC1 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.